drugset / Trial / NCT05497401
A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS
RandomizedParallel-groupTriple-blindTreatment
Summary
The efficacy of the allogeneic cell-therapy product MesenCure in addition to standard of care will be evaluated in comparison to placebo control in 300 moderate to severe Covid patients
Timeline
- Start
- 2026-04
- Primary completion
- 2028-06
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MesenCure | Cell therapy | — | — |